Holen Sie sich die Stockscreener-App
6.59
0.60%
-0.04
Abeona Therapeutics Inc Aktie (ABEO) Neueste Nachrichten
What analysts say about Abeona Therapeutics Inc. stockExponential return rates - PrintWeekIndia
Abeona Therapeutics Inc. Stock Analysis and ForecastDynamic profit expansion - Autocar Professional
Abeona targets treating 10–14 ZEVASKYN patients in 2025 while securing $155M PRV sale to extend runway - MSN
What drives Abeona Therapeutics Inc. stock priceRapid market gains - Jammu Links News
Abeona Therapeutics Amends Loan Agreement with Avenue - TipRanks
Abeona Therapeutics lowers loan interest rate and issues warrants in loan amendment By Investing.com - Investing.com South Africa
Abeona Therapeutics lowers loan interest rate and issues warrants in loan amendment - Investing.com
Is Abeona Therapeutics Inc. a good long term investmentMarket-leading growth rates - Jammu Links News
Loss-Making Abeona Therapeutics Inc. (NASDAQ:ABEO) Set To Breakeven - simplywall.st
Abeona Therapeutics’ Gene Therapy Trial for MPS IIIA: A Promising Update - TipRanks
HC Wainwright Reiterates Buy Rating for Abeona Therapeutics (NASDAQ:ABEO) - MarketBeat
ZEVASKYN™ Gene Therapy Now Available at New Qualified Treatment Center in San Francisco Bay Area - The Manila Times
Abeona Therapeutics Announces Activation of Lucile Packard Children’s Hospital Stanford as Qualified Treatment Center for FDA-Approved ZEVASKYN Therapy for RDEB - Quiver Quantitative
Bio-Techne's Simple Western™ Technology Utilized in Recent FDA Approval of ZEVASKYN™ Cell-Based Gene Therapy - The Malaysian Reserve
Bio-Techne's Simple Western Enables Breakthrough FDA Approval for Rare Skin Disease Gene Therapy - Stock Titan
US FDA declines to approve Ultragenyx's gene therapy for rare genetic disorder - Reuters
(ABEO) Trading Report - news.stocktradersdaily.com
Abeona Therapeutics Executives Unload Massive Stock Holdings! - TipRanks
Farmer Mac (AGM) CFO Aparna Ramesh resigns; Gregory Ramsey named interim | ABEO SEC FilingForm 4 - Stock Titan
Abeona Therapeutics added to U.S. Small-cap Russell 2000 and Russell 3000 Indexes - MSN
Abeona sells Rare Pediatric Disease PRV for $155M - MSN
Abeona Therapeutics Sells Priority Review Voucher for $155M - The Globe and Mail
Abeona Therapeutics' PRV Sale: A Strategic Move to Fuel Gene Therapy Growth - AInvest
Abeona therapeutics closes sale of priority review voucher for $155 million - Investing.com
Abeona Therapeutics Gets $155 Million From Sale of FDA Priority Review Voucher; Shares Up Pre-Bell - MarketScreener
Abeona Therapeutics Inc. Closes $155 Million Sale of Rare Pediatric Disease Priority Review Voucher - Quiver Quantitative
Abeona Therapeutics® Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million - The Manila Times
Abeona Therapeutics Announces Option Exercise by Beacon Therapeutics for Novel Aav204 Capsid for Ophthalmology Gene Therapy - MarketScreener
Beacon Therapeutics licenses Abeona’s AAV204 capsid for retinal therapies - Investing.com
Abeona Therapeutics® Announces Option Exercise by Beacon - GlobeNewswire
Beacon Therapeutics licenses Abeona’s AAV204 capsid for retinal therapies By Investing.com - Investing.com UK
Abeona Therapeutics® added to Membership of U.S. Small-cap Russell 2000® Index and Broad-market Russell 3000® Index | ABEO Stock News - GuruFocus
Abeona Therapeutics Inc.(NasdaqCM: ABEO) added to Russell 3000E Growth Index - MarketScreener
Health Rounds: Inhaled insulin as good as injection for children at mealtime - Reuters
Abeona Therapeutics® Announces Publication in The Lancet of - GlobeNewswire
Abeona Therapeutics' Zevaskyn Vs. Krystal Biotech's Vyjuvek (KRYS, ABEO) - Seeking Alpha
Trend Tracker for (ABEO) - news.stocktradersdaily.com
ABEONA THERAPEUTICS Executives Sell Shares to Cover Tax Obligations - TradingView
Abeona Therapeutics Officer Sells Shares to Cover Tax Obligations - TradingView
Abeona Therapeutics Inc (NASDAQ:ABEO) Shares Purchased by Bank of America Corp DE - Defense World
Abeona Therapeutics: Substantially Undervalued Post-FDA Approval (Rating Upgrade) - Seeking Alpha
Abeona Therapeutics at Jefferies Conference: ZivaSkin’s Promising Launch By Investing.com - Investing.com Canada
Abeona Therapeutics (ABEO) Gains "Outperform" Rating from Oppenheimer | ABEO Stock News - GuruFocus
Abeona Therapeutics (ABEO) Gains Oppenheimer's Outperform Rating with Promising Outlook | ABEO Stock News - GuruFocus
Abeona Therapeutics (ABEO) Gains Oppenheimer's Outperform Rating - GuruFocus
Abeona Therapeutics (ABEO) Grants Equity Awards to New Employees - GuruFocus
Abeona Therapeutics Announces New Employee Inducement Grants - MarketScreener
Abeona Therapeutics (ABEO) Grants Equity Awards to New Employees | ABEO Stock News - GuruFocus
Abeona Therapeutics® Announces New Employee Inducement Grants Un - GuruFocus
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Abeona Therapeutics Awards Stock Grants Worth 11,500 Shares: New Employee Compensation Details Revealed - Stock Titan
Abeona Therapeutics® to Present at the Jefferies Global Healthcare Conference - GlobeNewswire
Abeona Therapeutics® to Present at the Jefferies Global Healthca - GuruFocus
0.59%
0.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):